Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Novel Anti-PTEN Rabbit Monoclonal Antibody Optimized for Immunohistochemistry Testing

By BiotechDaily International staff writers
Posted on 16 Sep 2013
Image: SP218 staining PTEN loss on colon adenocarcinoma sample (Photo courtesy of Spring Bioscience, Inc.).
Image: SP218 staining PTEN loss on colon adenocarcinoma sample (Photo courtesy of Spring Bioscience, Inc.).
Cancer researchers now have available a rabbit monoclonal antibody for the protein produced by the PTEN tumor suppressor gene that has been optimized for immunohistochemistry (IHC) testing.

PTEN is one of the most commonly lost tumor suppressors in human cancer. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, and reduced expression is found in many other tumor types such as lung and breast cancer. When the PTEN enzyme is functioning properly, it acts as part of a chemical pathway that signals cells to stop dividing and causes cells to undergo programmed cell death (apoptosis) when necessary. These functions prevent uncontrolled cell growth that can lead to the formation of tumors. There is also evidence that the protein made by the PTEN gene may play a role in both cell movement and adhesion of cells to surrounding tissues.

A new tool for the study the PTEN enzyme was developed by Spring Bioscience (Pleasanton, CA, USA). Spring has recently added the SP218 anti-PTEN rabbit monoclonal antibody to its portfolio of antibodies for cancer research.

The SP218 anti-PTEN monoclonal antibody for IHC on FFPE (formalin-fixed, paraffin-embedded) tissue is available in 0.1, 0.5, and 1.0 mL concentrate configurations, as well as in a 7.0-mL ready-to-use format. Recommended staining protocols are available for manual, semi-automated, and fully automated platforms. SP218 is for research use only and not for use in diagnostic procedures.

"SP218's robust and consistent performance with IHC analysis is particularly important given PTEN's potential as a companion diagnostic biomarker," said Michael Rivers, general manager of Spring Bioscience. "With SP218, we are seeking to set a new gold standard across the industry by offering an extremely sensitive, highly specific antibody optimized for IHC testing that will allow researchers and pathologists to interpret PTEN status with utmost confidence. For our customers, this means we are continuing to offer unparalleled value through superior tests that lead the market in innovation, reliability, and quality."

Related Links:
Spring Bioscience



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.